AURA.US Aura Biosciences Inc

Healthcare Biotechnology USA Stocks
7.11 USD
Close of Nov 14, 2026
4.73 9.54
Market cap
USD 740M
P/E
-
P/B
2.58x
ROE
-51.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is AURA.US undervalued?

Graham number

The Graham number of Aura Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Aura Biosciences Inc fundamental analysis

No fundamental analysis for Aura Biosciences Inc yet.

Aura Biosciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Aura Biosciences Inc

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology …

Full company profile